Daiichi Sankyo Launches Japan's Third Alzheimer's Disease Drug
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo has launched its Alzheimer's disease drug Memary (mementine), which has a different mechanism of action than Eisai Co. Ltd's Aricept (donepezil) and Janssen Pharmaceutical KK's Reminyl (galantamine). Memary can be used in combination with Aricept or Reminyl